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General Introduction
  Rheumatoid arthritis (RA) is a systemic infiaimnatory disease that mainly affects
anicular synovial tissue. It is thought that autoimmunity is induced in RA patients
when hereditary factors are combined with various environmental ones, resulting in the
onset of chronic inflamrnation. However, the etiology has not yet been elucidated
completely, and prevention is still impossib}e. RA oecurs all around the world and in
every race. This disease can develop at any age. Since there is no reliable diagnostic test
for RA, the incidence and prevalence of this disease have been investigated by using
certain diagnostic criteria that were developed for the purpose of disease classification.
The most commoniy used criteria are the American Rheumatism Association Criteria
for Classification of Rheumatoid Arthritis (revised in 1987)i). The prevalence of RA is
estimated to be O.3'1.5 "/o, although it varies depending on the strictness of the criteria
used2). If this range is applied to the Japanese population, the number of RA patients in
Japan ean be estimated as 380,ooO to 1,900,OOO. The results of a recent survey
conducted by a research group of the Japanese Mmistry of Health and Welfare
suggested that RA patients account for O.54 % of females and O.11 "/o of males, and that
the total number of RA patients is around 7co,OOO.
   Guidelines for treatment of RA were prepared and published in 2oo4 by a research
group ef the Japanese ]Ylinistry of Health, Labour and Welfate. These new guidelines
cover a great variety of drugs, including the newly developed biologieal preparations, as
well as steroids, disease'modifying anti'rheumatie drugs (DMARDs), and nonsteroidal
anti'inflammatory drugs (NSAIDs) that have leng been used for the treatment of
rheumatic disease3). Although the impertance of NSAIDs in the treatment of RA has
been decreasing, they are still convenient drugs to employ for an anti'inflammatory and
-
4-
analgesic effect.
  The progression of articular lesions in RA can be classified into three stages: onset of
autoimmunity, synovial inflammation, and articular destruction. With the onset of
autoimmunity, there is accumulation ofimmunocompetent cells, such as lymphocytes
(mainly CD4' T cells) and macrophages in the synovium, which is followed by the
development of synovial infiammation. Synovial infiammation is elassified into acute
inflammation and chronic hyperplasia of the synovial membrane associated with
neovascularization. Synovial tissue is essential for normal joint function. In RA, there is
hyperplasia ofthe synovium and formation of granulation tissue (paimus) together with
infiltration of inflammatory cells, such as T cells and macrophages. Formation of
pannus is presumably ascribable to an imbalance between the factors promoting
hyperplasia, including various cytokines, and antihyperplastic factors that include the
induction of apoptosise. Activated pannus may eventually cause the destruction of
bone and cartilage via the release of various mediators, including inflammatory
cytokines such as interleukin (IL)'IB and tumor necrosis factor (TNF)ct5). Effective
drugs for each of these stages ofjoint involvement have been developed. Physical and
biochemical inhibition of synovial hyperplasia as the starting point of articular
destruction may be an effective radical treatment for RA6).
  It was reported that articular destruction was significantly inhibited when
15'deoxy'Ai2•i4'prostaglan(lin J2 (15dPGJal, an endogenous ligand of peroxisome
proliferator'activated receptor (PPARly, which is an intranuclear transcription factor
that induces apoptosis ofRA'derived synovial fibroblasts, was administered to rats with
arthritis7), while arthritis in miee was inhibited by administration of an anti'Fas
antibody that induces apoptosis8). Although these fuidings suggest the possibility of
-
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achieving an antirheumatic effect by inhibiting hyperplasia of the synovial membrane,
there have been no clinical studies targeting this endpoint.
  The mechanism of action of NSAIDs generally involves the inhibition of
cyclooxygenase (COX) at sites of inflammation. As a result, these drugs exhibit a
therapeutic effect by inhibiting the production ofprostaglandin (PG)s, including PGE2
and PGI2 (representative inflammatory mediators). In the treatment of RA, NSAIDs are
used as adjuvant therapy with an analgesic and anti'inflammatory effect via inhibition
of COX. These agents were not considered to have a so'called anti'rheumatic effect,
including inhibition of progressive joint destruction and induction of remission, unlike
some anti'rheumatic drugs. However, certain NSAIDs have been reported to inhibit
synovial hyperplasia by inducing the apoptosis of human synovial fibroblasts. We
previously found that some conventional NSAIDs (diclofenac, indometacin, oxaprozin,
and zaltoprofen) induced the apoptosis of synovial fibroblasts ftom RA patients via
activation of PPARy and thus inhibited hyperplasia of these cells9). We also
demonstrated that aspirin and sodium salicylate could induce apoptosis of RA synovial
fibroblasts, although only at higher concentrationsiO). As mentioned above, several
NSAIDs have not oniy exhibited an analgesielanti"infiammatory effeet, but have also
show an inhibitory effect on synovial fibroblast hyperplasia in several fundamental
studies. However, these drugs only exhibited an apoptosis'inducing effect when
administered at a relatively high concentration. Therefore, if agents with a stronger
activity were developed, it will be possible to inhibit synovial hyperplasia.
   COX'2 is an isozyme of COX that is rnarkedly indueed by inflammatory stimuli and
is considered to be closely related to the process of inflammation. Celecoxib, which
selectively inhibits COX'2, was developed by investigating the three'dimensional
-
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structure of COX and it has been marketed in more than 70 countries. In addition to
inhibition of COX'2, celecoxib has been reported to inhibit the proliferation of cells from
various cancers mainly by inducing apoptx)sisii"i6). We previously investigated the
apoptotic effect of six selective COX'2 inhibitors on human colorectal cancer cells, and
found that only celecoxib induced apoptosis, which was induced via a direct effect and
was unrelated to COX inhibitioni7).
   Based on these findings, drugs inhibiting the hyperplasia of synovial fibroblasts
from RA patients were investigated in the present study. In chapter 1, six selective
COX'2 inhibitors (including celecoxib) were compared with respect to the induction of
apoptosis and inhibition of PGE2 production. In chapter 2, a novel agent (TTIOI) that
was developed based on investigation of celecoxib, was assessed for the same
parameters. In chapter 3, the apeptotic activity of triptolide, an active ingredient of
'Itipterygium wilfordli Hook F (TWHF: used clinically in China for its antirheumatic
activity) was investigated using synovial fibroblasts frDm RA patients.
-
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Chapter 1 Effects of selective COX-2 inhibitors
1. Introduction
       Arachidonic acid is released from the cell membrane phospholipids by
phospholipase A2. COX is a rate'limiting enzyme that metabolizes arachidonic acid to
various physiologically active substances such as PGs. Several studies have shown that
COX has 2 isoenzymes, which diiifer with respect to their basal expression, tissue
1ocalization, and induction during infiammationi8•i9År. The existence of 2 COX
iscenzymes with differing characteristics may help to explain differences in the
pharmaco}ogical profiles of various NSAIDs and may also have important clinical
consequences. COX'1 is constitutively expressed by various cells, whereas COX'2 is an
inducible enzyme and is found predominantly at sites of infiammation. It has been
proposed that the inhibition of COX'1 in gastric mucosal cells and the resultant
decrease of PG synthesis leads to weakening of 1oeal mucosal proteedve mechanisms
and accounts for the sigrrificant gastrointestina} toxicity of NSAIDs20). COX'2 shows an
increase in activity with the onset of infiammation that leads to increased production of
PGs, so it should theoretically be a better therapeutic target than COX'12i).
       The recently developed selective COX'2 inhibitors (coxibs) are now being used
as anti'inflammatory agents to treat patients with RA andlor osteoarthritis (OA), and
are asseciated with a lower incidence of gastrointestinal complications compared with
conventional NSAIDs. 'I)wo large'scale clinical trials of eelecoxib22) and rofecoxib23) have
provided evidence that these coxibs can reduce the incidence of severe upper
gastrointestinal toxicity in patients with RA and/or OA.
       It is generally accepted that NSAIDs regulate inflammation via the inhibition
ofCOX'2, but some novel mechanisms ofaction have recently been discussed. Jiang24) et
-
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al. found that activation of PPARy, a nuclear transcription factor, inhibited the
production ofcytokines in human monocytes. They reported that several PPARy ligands,
including NSAIDs such as indometacin, could activate this receptor. We recently found
that several NSAIDs, such as indometacin, diclofenac, and oxaprozin, induced apoptosis
of RA synovial fibroblasts in association with PPARy activation9). In contrast, results
reported by Yin25) et al. suggest that aspirin and sodium salicylate may suppress
inflammation not only by inhibition ofCOX, but also by inhibition ofinhibitor ofnuclear
factor (NF)'icB kinase 'B in Jurkat cells. These findings suggest the existence of other
mechanisms besides COX inhibition for the antirheumatic activity of NSAIDs.
       RA is characterized by extensive inflammation and proliferation of the
synovium in various joints. Nishioka26) et al. have suggested that stimulation of
proliferation by TNFct and induction of apoptosis by Fas ligand play an important role
in regulating the growth of rheumatoid synovial tissue. Although NSAIDs (even
selective COX"2 inhibitors) are generally considered to have little disease'modifying
effect in RA, some NSAIDs have been reported to suppress the proliferation of cells by
induction of apoptosis. Selective COX'2 inhibitors are relatively safe drugs, even at
higher doses. Accordingly, I investigated whether selective COX'2 inhibitors could cause
apoptosis of RA synovial fibroblasts.
-
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2. Results
2'1 Effects of selective COX'2 inhibitors on prostaglandin E2 production.
    I investigated the effect of six selective COX'2 inhibitors on PGE2 production by
synovial fibroblasts from patients with RA. As shown in Figure 1, selective COX'2
inhibitors (O.Ol'10 pM) caused suppression of PGE2 production stimulated by the
addition of 3 pM arachidonic acid, and the suppression was concentration dependent.
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Figure 1. Effects of selective cyclooxygenase 2 (COX-2) inhibitors on prostaglandin E2 (PGE2)
production by rheumatoid arthritis (RA) synovial fibroblasts. Cells were incubated for 1 hour at
370C with various concentrations ofeach selective COX-2 inhibitor (open bars = O.O1 pM; dotted
bars = O.1 pM; hatched bars =1 pM; solid bars = 10 ptM). Arachidonic acid (3 pM) was then
added and incubation was continued for another 30 minutes, after which the PGE2 level in the
culture medium was measured by enzyme immunoassay. Representative results from 3
independent experiments are shown; values are the mean Å} S.D. from triplicate cultures. The
PGE2 level in the control cultures was 12.3 Å} 1.3 nglmL.
2'2 Effects ofselective COX'2 inhibitors on cell proliferation
    To determine whether selective COX'2 inhibitors had an antiproliferative effect on
RA synovial fibroblasts, I examined the effect of these drugs on cell proliferation (DNA
synthesis) by measuring the incorporation of 5'bromo'2"deoxyuridine (BrdU) (Figure 2).
Celecoxib suppressed the proliferation of RA synovial fibroblasts in a concentration
-
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dependent manner and strongly inhibited cell proliferation, while etodolac, meloxicam,
nimesulide, and NS'398 had some inhibitory effect at higher concentrations. Rofecoxib
at concentrations up to 100 pM had no effect on cell proliferation.
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2-3 Effects ofselective COX'2 inhibitors on cell viability
     Since some selective COX-2 inhibitors suppressed the proliferation of RA synovial
fibroblasts, I next evaluated the effect of these drugs on cell viability, using a sulfonated
tetrazolium salt, 2'(4'iodophenyl)'3'(4'nitrophenyl)'5'(2,4'disulfophenyl)'2H"
tetrazolium monosodium salt (WSTI) assay. Celecoxib reduced cell viability in a
concentration'dependent manner (Figure 3). In contrast, etodolac, meloxicam,
nimesulide, NS'398, and rofecoxib at concentrations up to 100 pM had little effect on
cell viability.
      1 le loo
       Concentration (pM)
      inhibitors on proliferation of RA synovial fibroblasts. Cells
       inhibitor (at 3, 10, 30, 40, and 1OO pM). Cell proliferation
incorporation of 5-bromo-2'-deoxyuridine (BrdU). Representative
periments are shown; values are the mean Å} S.D. from triplicate
= etodolac; A = meloxicam; A = nimesulide; e = rofecoxib;
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     Since the incubation time can also influence cell viability, I examined the effect of
celecoxib and rofecoxib (at 30 pM) on the viability of RA synovial fibroblasts after
incubation for 96 hours. Cell viability was reduced to 21 O/o after incubation with
celecoxib, versus 98 O/o after incubation with rofecoxib.
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Figure 3. Effects of selective COX-2 inhibitors on viability of RA synovial fibroblasts. Cells
were incubated for 24 hours with each inhibitor (at 3, 1O, 30, 40, and 1OO pM). Viability was then
measured by the WST-l assay. Representative results from 4 independent experiments are
shown; values are the mean Å} S.D. from triplicate cultures. e = celecoxib; O = etodolac; A
=
meloxicam; A =nimesulide; e =rofecoxib; Q =NS-398.
2'4 Effects of selective COX'2 inhibitors on DNA fragmentation
     To determine whether the decrease in RA synovial fibroblast viability was caused
by apoptosis, I examined the effect of selective COX'2 inhibitors on DNA fragmentation,
a hallmark of apoptosis, using a quantitative enzyme'linked immunosorbent assay
(ELISA) that specifically detected cytoplasmic histone-associated DNA fragments,
mononucleosomes, and oligonucleosomes. As shown in Figure 4, celecoxib induced DNA
fragmentation, with the peak effect occurring with a concentration of 40 pM. With
-
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celecoxib at 100 pM, DNA fragments were released into the culture medium (data not
shown), indicating that the cells had undergone secondary (type 2) necrosis, which
usually occurs after apoptosis during in vitro experiments. In contrast, the other
selective COX'2 inhibitors did not induce DNA fragmentation at any concentration.
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 Figure 4. Effects of selective COX-2 inhibitors on DNA fragmentation in RA synovial
 fibroblasts. Cells were incubated for 24 hours with each inhibitor (at 3, 10, 30, 40, and 100 pM).
 DNA fragments in the cytoplasm were then measured by enzyme immunoassay. The fold
 induction of DNA fragmentation is shown reiative to the control value (untreated cells).
 Representative results from 4 independent experiments are shown; values are the mean Å} S.D.
 from triplicate cultures. e = celecoxib; O = etodolac; A = meloxicam; A = nimesulide;
 " - rofecoxib; Q =NS-398.
2-5 Effects ofcaspase inhibitors on celecoxib'induced apoptosis
     To investigate whether the caspase cascade participated in the induction of
apoptosis by celecoxib, I examined DNA fragmentation after RA synovial fibroblasts
were cultured in the presence of celecoxib with or without caspase inhibitors. The
proapoptotic effect of celecoxib (40 pM) was abolished by addition of caspase'3,
                                    -13-
caspase'8, or caspase'3/7 inhibitors (Figure 5).
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 Figure 5. Effects ofcaspase inhibitors on celecoxib-induced DNA fragmentation in RA synovial
 fibroblasts. Cells were incubated with celecoxib (40 pM) and each caspase inhibitor
 (Z-DEVD•-FMK [a caspase-3 inhibitor], Z-IETD-FMK [a caspase-8 inhibitor], and Z-VAD-FMK
 [a caspase-3f7 inhibitor]) for 24 hours at the indicated concentrations, after which DNA
 fragments in the cytoplasm were measured by enzyme immunoassay. The feld induction ofDNA
 fragmentation is shown relative to the control value (untreated cells). Representative results from
 2 independent experiments are shown; values are the mean and S.D. from triplicate cultures.
2'6 Effectofinterleukin'IPoncelecoxib'inducedapoptosis
     The effect of IL'IP on celecoxib'induced DNA fragmentation was also determined.
As shown in Figure 6, addition of IL'IP (1 ng/mL) to RA synovial fibroblasts cultures
caused slight enhancement ofcelecoxib'induced apoptosis.
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  Figure 6. of interleukin (IL) -IP on celecoxib-induced apoptosis in RA synovial
  fibroblasts. were incubated for 24 hours with or without IL-15(1 ngfmL), after which
  celecoxib (40 pM) or rofecoxib (100 pM) was added and DNA fragments in the cytoplasm were
  measured by enzyme immunoassay. The fold induction of DNA fragmentation is shown relative
  to the control value (untreated cells). Representative results from 2 independent experiments are
  shown; values are the mean Å} S.D. from triplicate cultures. e = celecoxib alone; O ==
  celecoxib and IL-1P; " =rofecoxib alone; O =rofecoxib and IL-IB.
2'7 Detection of apoptotic cells by terminal deoxynucleotidyl transferase'mediated
     dUTP nick end labelling (TUNEL) assay
     To confirm the proapoptotic effect of celecoxib, cell morphology was examined and
the TUNEL assay was applied. Morphologic changes of RA synovial fibroblasts are
shown in Figure 7. Cells treated with celecoxib became rounder, exhibited shrinkage,
and became separated from adjacent cells. As shown in Figure 8, TUNEL positive cells,
accounting for 38 e/o of the total cells present, were observed after incubation for 24
hours with 40 ptM celecoxib. In contrast, TUNEL staining was negative when RA
synovial fibroblasts were incubated with the other selective COX'2 inhibitors (100 pM)
                                    -15-
and was also negative in untreated cells. These results suggested that celeeoxib caused
a decrease of RA synovial fibroblast proliferation by inducing apoptosis.
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Figure 7. Morphologic changes in RA synovial fibroblasts. Cells were incubated for 24 hours a,
without any COX-2 inhibitors or with b, celecoxib (40 uM), c, etodolac (1OO pM), d, meloxicam
(100 pM), e, njmesulide (100 pM), f, NS-398 (100 pM), or g, rofecoxib (100 pM). Magnification
Å~ 200.
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 Figure 8. Detection of apoptosis in RA synovial fibroblasts, by the TUNEL assay. Cells were
 incubated for 24 hours a, without any COX-2 inhibitors or with b, celecoxib (40 pM), c, etodolac
 (1OO yM), d, meloxicam (1OO pM), e, nimesulide (100 pM), f, NS-398 (100 pM), or g, rofecoxib
 (100 pM). Apoptotic cells exhibiting TUNEL staining are brown; normal cells counterstained
 with methyl green are blue. Magnification Å~ 200.
2'8 Effects of selective COX"2 inhibitors on peroxisome proliferator'activated receptor
     (PPAR)y activation
     To explore whether PPARy activation was involved in the apoptotic effect of
celecoxib, I performed a luciferase reporter gene assay in which RA synovial fibroblasts
were co-transfected with a PPRE"driven luciferase reporter plasmid and a PPARy
expression plasmid. As shown in Figure 9, PPARy ligands (troglitazone and
-
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indometacin) induced significant PPRE"driven luciferase activity in
contrast, celecoxib and NS-398 had no effect on PPARy activity.
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Figure 9. Effect of
proliferators-activated receptor
with a peroxisome proliferator
expression plasmid, and an
known PPARy ligands or selective COX-2
described in Materials and
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selective COX-2 inhibitors on activation of peroxisome
   (PPAR) y in RA synovial fibroblasts. Cells were cotransfected
   response element-driven luciferase reporter plasmid, a PPAR7
internal control plasmid. Transfected cells were then treated with
           inhibitors, and luciferase activity was determined as
Methods. The fold activation of PPARy is shown relative to the
  Representative results from 3 independent experiments are shown;
  from triplicate cultures. e = celecoxib; Q = NS-398; 1 =
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3. Discussion
       In this chapter, I reported that the induction of apoptosis in RA synovial
fibroblasts by celecoxib. It has previously been suggested that both COX'1 and COX'2
are expressed by human RA synovial fibroblasts, and de novo synthesis of COX'2
protein has been observed in RA synovial fibroblasts even without addition of
stimulants27, 28). All 6 selective COX'2 inhibitors that I studied (celecoxib, etodolac,
meloxicam, nimesulide, NS'398, and rofecoxib) caused a År 90 O/o decrease in PGE2
production at a concentration of 10 FtM, which was sulficient to almost completely
inhibit COX-2. However, only celecoxib induced the apoptosis of RA synovial fibroblasts.
In addition, long time (96 hours) incubation of RA synovial fibroblasts with rofecoxib did
not affect cell viability. These results indicate that the induction of apoptosis by
eelecoxib was not associated with inhibition of COX'2 or suppression of PG production
in RA synovial fibroblasts.
       This study also showed that induction of DNA fragmentation in RA synovial
fibroblasts by celecoxib was abolished after the addition of inhibitors of caspase'3,
caspase'8, or caspase'3/7. Accordingly, the caspase cascade inay play an important role
in the induction of apoptosis of RA synovial fibroblasts by celecoxib
       Stimulation by IL'IS had a weak enhancing effect on celecoxib'induced
apoptosis of RA synovial fibroblasts. Tsuboi29) et al. reported that IL'IP inhibited Fas
antigen expression at the posttranscriptional level in RA synovial fibroblasts and
protected these cells ftom Fas antigen-mediated apoptosis. However, I found that
celecoxib'induced apoptosis was slightly enhanced by the addition of IL'IP. These
different responses to IL'IP might be explained by differences in the inducer of
apoptosis, i.e., anti'Fas antibody versus celecoxib.
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       PPARy is expressed by human RA synovial fibroblasts, and specMc ligands for
this receptor (troglitazone and 15dPGJal have been shown to inhibit the growth ofthese
cells by inducing apoptosis7•9). Activation of PPARy in monocytes is enhanced by some
NSAIDs, such as indometacin, fenoprofen, and ibuprofen, while this receptor is
activated in pre'adipoeytes by indometacin, fenoprofen, ibuprofen, and flufenamic acid
24•30). We recently found that induction of apoptosis in RA synovial fibroblasts by some
NSAIDs, such as indometacin, diclofenac, and oxaprozin, was associated with PPARy
activation9). Therefore, I examined whether selective COX'2 inhibitors could activate
this receptor in RA synovial fibroblasts. Celecoxib and NS-398 did not activate PPARy,
whereas indornetacin and troglitazone did, as demonstrated in the luciferase reporter
gene assay.
       A recent clinical study showed that celecoxib could reduce the number ofpolyps
in patients with familial adenomatous polyposis (FAP)3i). It was reported that
disruption of the COX'2 gene in the ApeA7i6 knoekout mouse, an animal model of human
familial polyposis, reduced the number and size of intestinal polyps32). 'IYeating ApcA7i6
knockout mice with selective COX'2 inhibitors also reduced the number of polyps 33).
Recently, Sonoshita3ab et al. reported that homozygous deletion of the gene encoding EP2,
a cell surface receptor for PGE2, caused a reduction in the number and size ofintestinal
polyps in ApcA7i6 knockout mice. Although the inhibition of polyp formation in these
mice was incomplete even after COX'2 gene knockout, these findings suggest that PGE2,
a terminal product of arachidonic acid metabolism via COX'2, may play a key role in the
progression of eolon tumor proliferation.
       In fact, 6 selective COX'2 inhibitors, celecoxib, etodolac, meloxicam, nimesulide,
NS-398, and rofecoxib, have demonstrated an in vivo antitumor effect in animal models
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of colon tumor33•35'39). The association of apoptosis with the antitumor effect was not
reported, and this effect of selective COX'2 inhibitors might be explained, at least in
part, by indirect mechanisms such as an anti'angiogenic action due to COX-2
inhibitionco•4i). However, it has been reported that eelecoxib has a proapoptotic effect on
cancer cells by COX'2"independent mechanisms, such as cell cycle arrest, blockade of
Akt activation, and inhibition ofbasic fibroblast growth factor42,43). As discussed above,
celecoxib inhibits the proliferation of RA synovial fibroblasts and induces apoptosis of
these cells through COX-2'independent and PPARy'independent mechanisms.
       Although the significance of such a COX'2 independent mechanism for the
induction of apoptosis in RA synovial fibroblasts remains to be studied, this unique
action of celecoxib implies a disease'modifying effect in RA. In the present study, I found
that celecoxib suppressed the proliferation of RA synovial fibroblasts and induced
apoptosis at relatively high concentrations (10'30 ptY[) when compared with the optimal
concentration for COX-2 inhibition (Figure 1). The mean maximum plasma
concentration ofcelecoxib in healthy volunteers was reported to be 1.4, 2.5, and 7.7 pM
after single doses of 100, 400, and 800 mg, respectively"). Therefore, this possible
disease"modifying effect of celecoxib could hardly be expected to occur with standard
oral administration. However, it might become possible to achieve such an effect if the
drug is administered directly into the synovial space or via a new delivery system.
Otherwise, a novel compound that induces apoptosis at clinically achievable
concentrations by mimicking the action ofcelecoxib may possibly be oftherapeutic value
in RA.
-
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4. Conclusion
       Celecoxib suppressed the proliferation of RA synovial
COX-2-independent and PPARy'independent induction of apoptosis.
fibroblasts by
-
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Chapter 2 Effect of TTIOI, derivative of celecoxib
1. Introduction
       Celecoxib is one ofthe NSAIDs that selectively inhibit COX'2. It is widely used
for treatment of RA with the expectation that an anti'inflammatory effect will result
from inhibiting the production of prostanoids, like PGE2, through the suppression of
COX'2 activity. In chapter 1, I had demonstrated that celecoxib induces the apoptosis of
synovial fibroblasts obtained from patients with RA.
       Apoptosis is considered to be one of the mechanisms regulating autoimmune
diseases such as RA45). In the pathogenesis ofRA, it is thought that the normal balance
between proliferation and apoptosis of synovial fibroblasts is lost, leading to hyperplasia
of these fibroblasts4. Activated synovial fibroblasts cause growth of synovium in the
anicular cavity along with angiogenesis, invade the adjacent bone, promote production
of inflammatory cytokines by infiammatory cells, and cause cartilage and bone
destruction6). Therefore, it has been shown that stimulation ofthe apoptosis of synovial
fibroblasts might be usefu1 for the treatment of RA 26• 46).
       Recently, celecoxib was reported to cause a significant reduction in the number
of colorectal polyps in patients with FAP3i), and it has attracted attention as an
antiproliferative agent in anima} and cell culture studies. We have previously shown
that celecoxib induces the apoptosis ofcolorectal carcinoma cellsi7). In addition, several
studies conducted by other investigators have demonstrated that celecoxib suppresses
the proliferation of various cells by inducing apoptosisii'i6), suggesting that the
proapoptotic action of celecoxib may be usefu1 for the chemoprevention of
tumorigenesisi3•i5). These effects may represent an action that is unique to the drug
celecoxib rather than being a class effect of COX'2 inhibitors
-
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       In chapter J, the concentration of celecoxib required to induce apoptosis of
synovial fibroblasts obtained from patients with RA was slightly higher than the blood
level of the drug achieved in healthy individuals44). Therefore, for adequately
proapoptotic activity to achieve an antirheumatic effect in clinical use, celecoxib may
need to be used administered at higher dose levels than those used clmically.
Accordingly, I have attempted to develop a drug with more potent apoptosis inducing
activity for this purpose. In this process, we synthesized two derivatives, TTIOI and
T201, and analyzed these proapoptotic reactions on synovial fibroblasts.
-
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2. Results
2' 1 Effect of TT IOI on cell proliferation
    'Ib determine whether TTIOI and [['T201 had an inhibitory effect on the
proliferation of RA or OA synovial fibroblasts, I first examined the infiuence of these
drugs on cell proliferation (DNA synthesis) by measuring the nuclear incorporation of
BrdU (Figure 10). [['rlOl inhibited the proliferation of both RA synovial fibroblasts
(Figure 10A) and OA synovial fibroblasts (Figure IOB) in a concentration'dependent
manner. TT201, celecoxib, and SC'236 also inhibited cell proliferation, but their effects
were weaker than that of T"rlOl. Rofecoxib had no effect on cell proliferation up to a
concentration of 100 M.
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Figure 10. Effect of the each drug on the proliferation of synovial fibroblasts obtained from
patients with rheumatoid arthritis (RA, panel A) and osteoarthritis (OA, panel B) incubated with
celecoxib (e), TTIOI (A), TT201 (M), SC-236 (Å~), or rofecoxib (O) for 24 hours. Then
proliferative activity was estimated from the nuclear incorporation ofBrdU, and was expressed as
a percentage of the control value (untreated cells). Data are the mean Å} S.D. for triplicate
cultures, and representative results from 3 independent experiments are shown
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2'2 Effect of 'I"r lQl on cell viability
    To determine whether 'Ill)101 and [['r201 had an infiuence on the viabMty of RA
synovial fibroblasts and OA synovial fibroblasts, I evaluated cell viability using the
WST1 assay (Figure 11). 'I"rlOl caused a marked decrease of the cell viability of both
RA synovial fibroblasts (Figure 11A) and OA synovial fibroblasts (Figure 11B) in a
concentration-dependent manner. The order of potency of the effect of each drug on cell
                                           '
viability was as follows: TIOI År celecoxib = SC-236 År 'I"r201 (for both types of cells).
Rofecoxib had no effect at all on cell viability.
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Figure 11. Effect of each test drug on the viability of synovial fibroblasts obtained from patients
with RA (panel A) and OA (panel B). Cells were incubated with celecoxib (e), TTIOI (A),
TT201 (O), SC-236 (Å~), or rofecoxib (O) for 24 hours. Then cell viability was determined by
the WST-1 assay and expressed as a percentage of the control value (untreated cells). Data are
the mean Å} S.D. for triplicate cultures, and representative results from 3 independent
experiments are shown.
2'3 Effect of 'IT IOI on DNA fragmentation
     TTIOI induced DNA fragmentation, the hallmark of apoptosis, in both RA
synovial fibroblasts (Figure 12A) and OA synovial fibroblasts (Figure 12B), and its effect
-
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was more potent than that of celecoxib or SC-236. 'lll]201 also induced DNA
fragmentation but was weaker than celecoxib. In contrast, rofecoxib did not induce any
DNA fragmentation.
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  Figure 12. DNA fragmentation in synovial fibroblasts from RA patients (panel A) and OA
  patients (panel B). Cells were incubated with celecoxib (e), TTIOI (A), TT201 ("), SC-236
  ( Å~ ), or rofecoxib (O) for 24 hours, after which cytoplasmic DNA fragmentation was measured
  by eniryme immunoassay and expressed relative to the control value (untreated cells). Data are
  the mean Å} S.D. for triplicate cultures, and representative resuks from 3 independent
  experiments are shown.
     The cell morphology was examined under a light microscope after exposure to
TTIO1 (Figure 13). When the cells were incubated with 7 pM 'I"T101 for 24 hours (Figure
13, C and D), distinctive morphological changes were observed, such as rounding and
shrinkage, and the cells became detached from their neighbors.
-
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Figure 13. Morphological changes of the synovial fibroblasts from RA patients (panels A and
C) or OA patients (panels B and D) as observed by light microscopy. Cells were incubated for
24 hours without (A, B) or with (C, D) TT1O1 at a concentration of 7 pM. Bar = 60 pm.
2'4 Effe ct of TT IO I on ca sp ase '3 activity
     Caspases are responsible for many of the biochemical and morphological changes
that occur during apoptosis, so I investigated whether TIOI induced the activation of
caspase'3 (a terminal enzyme in the apoptotic pathway). As shown in Figure 14,
incubation of RA synovial fibroblasts with 7 pM TTIOI for 24 hours induced the
activation of caspase'3, whereas this activation was completely blocked by incubation
with Z'IETD'FMK or Z"LEHD'FMK (inhibitors ofcaspase'8 and '9, respectively).
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Figure 14. Effect of TTIOI on caspase activity in RA synovial fibroblasts. Cells were cultured
for 24 hours in the absence of any of agents, or with 7 pM TTIOI alone, 7 pM TTIOI plus
Z-IETD-FMK (a caspase-p8 inhibitor), or 7 pM TTIOI plus Z-LEHD-FMK (a caspase-9
inhibitor), after which caspase activity was detected by using the CaspACE'M assay system (the
absorbance was measured at 405 nm). Data are the mean Å} S.D. from 3 independent
experiments. ', p Åq O.Ol vs. cells treated with TTIOI alone. Significance was evaluated by
Tukey's multiple comparison test.
2"5 Effects ofcaspase inhibitors on TTIOI-induced apoptosis
     Next, I examined the effects of these caspase inhibitors on the TTIOI'induced
apoptosis (Figure 15). Induction of DNA fragmentation in RA synovial fibroblasts by
TTIOI was suppressed by Z'DEVD'FMK Z'IETD'FMK, and Z'LEHD'FMK in a
concentration'dependent manner.
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Figure 15. Effects of TTIOI plus a caspase inhibitor on DNA fragmentation in RA synovial
fibroblasts. Cells were incubated with TTIOI withlwithout a caspase inhibitor for 24 hours,
after which the cytoplasmic DNA fragmentation was measured by enzyme immunoassay and
expressed relative to the control value (untreated cells). Data are the mean Å} S.D. for triplicate
cultures, and representative results from 3 independent experiments are shown. *, p Åq O.Ol vs.
cells treated with TTIOI alone. Significance was evaluated by Tukey's multiple comparison
test.
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2'6 Effect ofTTIOI on expression of apoptotic related protein
     I examined the effects ofthe test drugs on the expression ofBcl'2, which is linked
to inhibition of apoptosis47). Western blotting demonstrated expression of Bcl'2 by RA
synovial fibroblasts, and little change in the level of expression was seen after
treatment with any ofthe COX'2 inhibitors (Figure 16, top). I also studied the effects of
the each drug on cleavage of BID (a substrate of easpase'8) in RA synovial fibroblasts,
since truncated BID (tBID; 15 kDa) activates the mitochondrial proapoptotic pathway.
Full'length BID was expressed in RA synovial fibroblasts, but none of the test drugs
-
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caused cleavage ofBID under the conditions tested (Figure 16, bottom).
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Figure 16. Effects of TTIOI and celecoxi
synovial fib
with 7 pM TTIOI (lane 2), 100 pM TT201
extracts were prepared from the cells an
detected Bcl-2 (upper) or BID (lower), as descri
                                b on expression of Bcl-2 and cleavage of BID. RA
           roblasts were cultured for 6 hours without any agents (lane 1) or were incubated
                                  (lane 3), or 40 pM celecoxib (lane 4). Protein
                               d subjec ed to Westem blotting using an antibody that
                                     bed in Methods.
2'7 Effe ct of ro fe coxib on TT IO I'induced ap optosis
    To investigate whether the interaction between TTIOI and the COX'2 was related
to the induction of apoptosis, I studied the effect of pretreatment with another COX'2
inhibitor (rofecoxib) on TTIO1'induced apoptosis. One hour before the addition of'I"TIOI,
rofecoxib was added to cultures of human synovial fibroblasts at a concentration that
was sufficient to inhibit COX'2, and then DNA fragmentation was assessed as described
above. As shown in Figure 17, 'I"TIOI induced the same extent of apoptosis after
pretreatment with rofecoxib as that seen in the absence of COX'2 inhibition by
rofecoxib; this was true for both in RA synovial fibroblasts (Figure 17A) and OA synovial
fibroblasts (Figure 17B).
-
31-
  25
g
gt 2o
.T
.dls
g,
gio
g,,
  o
  50
? 45
.6'40E 3s
e. ,o
g 25
g. ,,
Eg 15
tgi,o
  o
           t 10 100
                                         1 le loe
             Concentration (pLM)
                                                    Concentration (-M)
  Figure 17. 7. Effect of rofecoxib on TTIOI-induced DNA fragrnentation. RA synovial
  fibroblasts (panel A) and OA synovial fibroblasts (panel B) were incubated with (continuous
  line)/without (broken line) 1 pM rofecoxib for 1 hour, and then were incubated in the
  presencelabsence of TTIOI (niangles) or celecoxib (diamonds) for 24 hours. Cytoplasmic
  DNA fragmentation was measured by enzyme immunoassay and expressed relative to the
  control value (untreated cells). Data are means Å} S.D. from triplicate cultures, and
  representative resuks from 3 independent experiments are shown.
2'8 Effect of 'IT IOI on prostaglandin E2 production
    I investigated the effect of each test drug on the production of PGE2 by RA
synovial fibroblasts. As shown in Figure 18, all of the drugs suppressed the production
of PGE2 (stimulated by the addition 3 idM[ of arachidonic acid) in a
concentration'dependent manner, but 'IVrlOl had the weakest suppressive effect on
PGE2 production.
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Figure l8. Effect of the test drugs on the production ofPGE2 by RA synovial fibroblasts. Cells
were stimulated with IL-1P (1 pglmL) for 24 hours, washed twice with PBS, and incubated for
1 hour at 370C with various concentrations ofcelecoxib ("), TTIOI (A), TT201 (M), SC-236
(X), or rofecoxib (O). Then arachidonic acid (3 pM) was added and incubation was continued
for another 30 minutes, after which the PGE2 level in the culture medium was measured by
enzyme immunoassay. Representative results from 3 independent experiments are shown, and
values are the mean Å} S.D. from triplicate cultures. The PGE2 level in control cultures was 38.0
Å} 5.9 nglmL.
2'9 Effect of 'I'I] 10 1 on ce ll viab ility of U937
     I examined the proapoptotic effect of TTIOI on U937, a human monocyte cell line.
As shown in Figure 19, 'I'rlOl as well as celecoxib induced cell death in U937 at almost
the same potency as those in synovial fibroblasts.
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Figure 19. Effect of each test drug on the viability of U937 cells. Cells were incubated with
celecoxib (e), T'TIOI (A), TT201 (M), or rofecoxib (O) for 24 hours. Then cell viability was
determined by the WST-1 assay and expressed as a percentage of the control value (untreated
cells). Data are the mean Å} S.D. for triplicate cultures, and representative results from 3
independent experiments are shown.
-
34-
3. Discussion
       In this chapter, [ITIOI, a novel celecoxib derivative, was shown to be a powerfu1
inducer of apoptosis in both RA synovial fibroblasts and OA synovial fibroblasts. The
potency of the inhibitory effect of TTIOI on cell proliferation, evaluated in terms of the
50 O/o effective concentration, was about 5'fold stronger than that of celecoxib for RA
synovial fibroblasts and 15'fold stronger for OA synovial fibroblasts. On the other hand,
the potency of TTIOI for inhibiting ICso (50 O/e InhibitoTy concentration) for COX'2 was
about 70'fold weaker than that of celecoxib. Thus, the proapoptotic activity of 'I"TIOI
was far stronger than that ofcelecoxib, whereas its COX'2 inhibitory activity was much
weaker. The proapoptotic activity of TTIOI was not altered by the binding of rofecoxib
with COX'2 after pretreatment of cultured cells with adequate concentrations of
rofecoxib (Figure 17). This allows us to rule out the possibility that binding of TTIOI to
COX-2 alters the structure of the enzyme and thus triggers apoptosis, suggesting that
the mechanism of apoptosis induction by TTIOI (as well as celecoxibÅr involves neither
COX'2 inhibition nor structural changes to the COX"2 molecule.
       I examined the proapoptotic effect of T'TIOI on U937, a human monocyte cell
line. [["TIOI as well as celecoxib induced cell death in U937 at almost the same potency
as those in synovial fibroblasts origure 19). A strong proapoptotic activity of 'I'rlOl on
human synovial fibroblasts might be one of the therapeutic approaches for rheumatoid
arthritisasÅr; however, a major improvement of 'I'TIOI itself andlor a proper targeting
technique for the drug wM be necessary for the clinical application.
       The study of adenocareinoma cells by Yamazaki et al.i7) demonstrated that
phosphorylation of Akt was only induced by celecoxib among the selective COX'2
inhibitors tested. Accordingly, the results of the present study using synovial fibroblast
-
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and OA synovial fibroblast differ from those ofprevious studies conducted using tumor
cell lines. Zhu et al.rs) synthesized various derivatives of celecoxib and examined each
derivative for induction of the apoptosis of PC'3 human prostate cancer cells. They
demonstrated that stronger inhibition of 3'phosphoinositide'dependent kinase'1,
upstream kinase of Akt activation, was associated with stronger induction of apoptosis
by celeeoxib analogs. In the present study, however, phosphorylated Akt was detected in
RA synovial fibroblasts, but it was unaffected by treatment with TTIOI or celecoxib
(data not shown). The different types of cells used in the two studies may explain the
differences in the proapoptotic effects of celecoxib.
       Apoptosis can be induced by internal (mitochondria'dependent) and external
(death receptordependent) pathways46). In the mitochondria'dependent pathway,
cytochrome c and apoptotic protease activating factor'1 are released from the
mitochondria and then bind to pro'caspase'9 to produce active caspase'9. In the death
receptordependent pathway, extraceilular death ligands bind to receptors and cause
activation of caspase'8. In this study showed that 'T"TIOI activated caspase'3, which is
at the end of the caspase cascade. Also, the induction of DNA fragmentation induced by
TTIO1 was suppressed by all ofthe caspase inhibitors tested (inhibitors ofcaspases'3, '8,
and '9). These findmgs suggest that the proapoptotic activity of TTIOI may involve two
signal trangduction pathways, i.e., both the internal (mitochondria'dependent) pathway
and the external (death receptordependent) pathway.
       The Bcl'2 family is thought to be involved in the regulation of these pathways
47). Bcl'2 prevents various apoptotic mitochondrial changes, including cytx)chrome c
release and loss of the membrane potentia149). Similar to the observations obtained in
our previous study using H'IL29 ce11si7), in which celecoxib did not affect Bcl'2
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expression, 'I"TIOI did not alter the expression of this anti"apoptotic protein. BID is a
specific substrate of caspase-8 involved in the external death receptor'dependent
pathway50•5i). Death receptor'dependent signals cause cleavage of cytosolic BID to
release tBID, which tBID translocates to mitochondria and thus transduces apoptotic
signals from the cytoplasmic membrane. Although TTIOI'induced DNA fragmentation
was suppressed by the addition of a caspase"8 inhibitor, I found that BID was not
degraded by TTIOI. It seems 1ikely that the mechanisms of mitochondria'mediated
apoptosis are not only regulated by Bcl'2 and BID but also by various other factors,
including Bad, Bim, and Bcl'XL47). I cannot rule out the involvement of such
mechanisms in the induction of apoptosis by TTIOI. Further studies including in vitro
experiments to investigate the mechanisms of 'M7101'induced apoptosis and in vivo
experiments to examine the antirheumatic activity using animal arthritis models
remain to be conducted.
       We modified the sulfonamide group of celecoxib to an
N'(2'aminoethyD'sulfonamide group when developing 'I"TIOI, whereas the tolyl group
in the terminal aromatic ring of celecoxib was modified to an aminophenyl group to
create T201. In the case of SC'236, this region was changed to a chlorophenyl group.
The structures of these celecoxib derivatives and rofecoxib are shown in Figure 20.
Whereas 'I'I)10! had a strong proapoptotic effect, the proapoptotic aetivity of'I"r201 for
RA and OA synovial fibroblasts was much weaker than that of celecoxib. This result
suggests that the methyl group of celecoxib may be essential for a proapoptotic effect on
synovial fibroblasts, when the inhibition of PGE2 production via COXt2 inhibition was
evaluated, 'Vr201 was less potent than celecoxib, but ICso of 'I"r201 was comparable
with that of rofecoxib. As suggested by Zhu et al. 48), the basic frame and electron
-
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density of'I"TIOI and T'T201 may influence their apoptosis"inducing activity and COX'2
inhibitory activity.
4. Conclusion
       TTIOI potently suppressed the proliferation of RA and OA synovial fibroblasts
by induction of apoptosis.
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Chapter 3 Effect of Triptolide
1. Introduction
       Extracts of'Itipterygium wilfordii Hook F (TWHF) have been reported to show
efiicacy in patients with a variety ofinflammatory and autoimmune diseases, including
RA52-5e. Previous studies have shown that several TWHF extracts can exert
immunosuppressive and anti'infiammatory effects in vivo. A chloroform extract of
TWHF suppresses type II collagen'induced arthritis in mice55), while
carrageenan'induced inflammation in rats is suppressed by the ethyl acetate extract of
,[[SWHF 56).
       The mechanism of action of these TWHF extracts has been investigated in vitro.
It has been shown that a multi'glycoside chloroform/methanol extract ofTWHF (GTW)
significantly inhibits proliferation and IL'2 productions by activated T cells57). GTW
also inhibits the produetion of IL-1, IL'6, IL'8, TNF-ct, and PGE2 by human peripheral
blood monocytes, as well as IgG, IL'2, and IL-4 production by human peripheral blood
lymphocytes58). Likewise, a chloroformlmethanol extract known as T2, significantly
inhibits the release ofPGE2 and IL'2 from human peripheral blood mononuclear cells59).
Maekawa et al.oo) have reported that the anti-rheumatic effect of GTW or TWHF might
be partly mediated through inhibition of PGE2 production by human synovial
fibroblasts due to downregulation of IL'IP'induced COX-2 mRNA expressions, possibly
via the inhibition of NF'KB activity. TWHF also inhibits T cell proliferation via the
induction of apoptosis 57).
       Thriptolide is an active compound that was identified in extracts of TWHF6i•62),
and its actions have been reported to be as follows: inhibition of IL'2 production by
mouse T cell hybridomas63), human peripheral blood lymphocytes, and Jurkat cells
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through nuclear inhibition of transcriptional activation of NF"KB6al; inhibition of
vascular endothelial growth factor expression65); suppression of NF'KB in T
lymphocytes66); inhibition of IL'8 expression in human bronchial epithelial cells64);
reduction of PGE2 production in human monocytes and RA synovial fibroblasts67); and
inhibition ofpro'matrix metailoproteinase'1 and '3 mRNA expressionss). Taken together,
these results suggest that triptolide may be an active compound from TWHF extracts
with immunosuppressive and anti'inflammatory effects. However, it has not been
clarified whether triptolide exerts a disease modifying effect on the pathophysiology of
RA. Since induction of apoptosis in synovial fibroblasts may be a possible therapeutic
strategy for RA, I examined whether triptolide could induce the apoptosis of RA synovial
fibroblasts.
- 40 -•
2. Results
2'1 Effect oftriptolide on cell proliferation
   First, I examined effect of triptolide on cell proliferation (DNA synthesis) by
measuring the incorporation of BrdU (Figure 21) using an ELISA. Triptolide caused
marked suppression of cell proliferation iri a concentration"dependent manner and it
was almost completely inhibited at 100 nlS([. In contrast, the other drugs that were
tested, such as bucillamine, D-penicillamine, and methotrexate, did not suppress the
proliferation ofRA synovial fibroblasts. The mean (Å} S.D.) value ofICso of7 independent
experiments was 20.4 Å} 2.4 nM.
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Figure 21. Effects of triptolide and anti-rheumatic drugs on the proliferation of RA synovial
fibroblasts. Cells were incubated with triptolide ("), bucillamine (A), methotrexate (e), or
D-penicillamine (A) for 24 hours. Then cell proljferation was estimated from the incorporation
ofBrdU and calculated as a percentage ofthe control value (untreated cells). Data are the mean Å}
S.D. for triplicate cultures and representative results from 7 independent experiments are shown.
2-2 Effect oftriptolide on cell viability
    To determine whether triptolide had an in fluence on the viabMty of RA synovial
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fibroblasts, I evaluated the effects ofvarious anti-rheumatic drugs on cell viability using
WSTI assay. Ttiptolide caused a marked decrease of cell viability in a concentration
dependent manner (Figure 22), while bucillamine, D-penicillamine, methotrexate,
sulphasalazine, and sodium aurothiomalate did not decrease viability at a
concentration of 10 pM. The mean (Å} S.D.) value of ICso of 6 independent experiments
was 74.3 Å} 9.5 nM.
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    of triptolide and anti-rheumatic drugs on the viability of RA synovial
  were incubated with triptolide (e), bucillamine (A), methotrexate (e),
 (A), sodium aurothiomalate (Q), or sulphasalazine (O) for 24 hours. Then
                 assay and calculated as a percentage of the control value
 Data are the mean Å} S.D. for triplicate cultures and representative results from 6
Figure 22. Effects
fibroblasts. Cells
D-penicillamine
viability was measured by the WST-1
(untreated cells).
independent experiments are shown,
2-3 Effect oftriptolide on DNA fragmentation
     [[b determine whether the decrease of viability and suppression of proliferation
when RA synovial fibroblasts were treated with triptolide was related to apoptosis, I
examined the effect of triptolide on DNA fragmentation (a hallmark of apoptosis). An
ELISA that specifically detected cytoplasmic histone'associated DNA fragments,
-
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mononucleosomes and oligonucleosomes, was used to quantitatively analyze DNA
fragments. As shown in Figure 23, triptolide induced DNA fragmentation in cultured
RA synovial fibroblasts, while bucillamine, D-penicillamine, and methotrexate did not
affect cellular DNA. The mean (Å} S.D.) value of triptolide concentration at a half of
maximum fold induction of 5 independent experiments was 35.9 Å} 16.3 nM.
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    Figure 23. Effects oftriptolide and anti-rheumatic drugs on DNA fragmentation of RA synovial
    fibroblasts. Cells were (A), methotrexate (e), or
    D-penicillamine (A) for 24 hours, after which fragmented DNA in the cytoplasm was measured
    by enzyme immunoassay and the fold induction ofDNA fragmentation was calculated relative to
    the control value (untreated cells). Data are the mean Å} S.D. for triplicate cultures and
    representative results from 5 independent experiments are shown.
2-4 Detection of apoptotic cells by TUNEL assay
    Cell morphology was observed with a light microscope after treatment of RA
synovial fibroblasts with triptolide (Figure 24). When synovial fibroblasts were
incubated with triptolide (100 nM) for 24 hours, distinctive morphological changes
occurred, such as cellular rounding, shrinkage, and membrane blebbing, and the cells
became separated from neighboring cells (panel b). The TUNEL assay was used to
O C).Ol O.l
             i:onc p-.mts"ation
 incubated with triptolide ("),
(pm1)
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confirm the apparent proapoptotic effect of triptolide. As shown in panel d,
TUNEL-positive cells were observed after incubation with 100 nM triptolide for 24
hours, accounting for 66 C/o of the cultured RA synovial fibroblasts. These results
suggested that tri' ptolide caused a decrease of RA synovial fibroblasts proliferation by
the induction of apoptosis.
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 Figure 24. Morphological changes ofRA synovial fibroblasts (a, b) and detection ofapoptosis by
 the TUNEL assay (c, d). Cells were incubated for 24 hours without (a, c) or with (b, d) triptolide
 at 100 nM. Brown cells are apoptotic cells that show TUNEL staining, while blue cells are
 nomnal cells stained with methylgreen. Original magnification Å~ 200.
2J5 Effect oftriptolide on caspase-3 activity
     Caspases are responsible for many of the biochemical and morphological changes
that occur during apoptosis, so I investigated whether triptolide induced the activation
of caspase-3 in RA synovial fibroblasts. As shown in Figure 25, incubation of RA
synovial fibroblasts with 100 nM triptolide for 24 hours induced the activation of
caspase-3, while activation was completely blocked by incubation with the pan-caspase
inhibitor Z-VAD-FMK.
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Figure 25. Effect of triptolide on caspase activity in RA synovial fibroblast. Cells were cultured
without agents for 24 hours, or were incubated with 100 nM triptolide or 100 nM triptolide plus
10 pM Z-VAD-FMK, and then caspase activity was measured by the CaspACE'M assay system
as the absorbance at 405 nm. Data are the mean Å} S.D. for 3 independent experiments. ", p Åq O.O1
versus untreated control cells and versus cells treated with triptolide plus Z-VAD-FMK.
Significance was evaluated by Student's t-test with a Bonferroni's correction.
2'6 Effects ofcaspase inhibitors on triptolide"induced apoptosis
    I then examined effects of caspase inhibitors on triptolide"induced apoptosis in RA
synovial fibroblasts. Triptolide'induced DNA fragmentation in RA synovial fibroblasts
was suppressed by Z'DEVD'FMK, ZIETD'FMK, and Z'LEHD"FMK in concentration
dependent manner (Figure 26).
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                               Triptolide 1OO nM
 Figure 26. Effects of triptolide and caspase inhibitors on DNA fragmentation in RA synovial
 fibroblasts. Cells were incubated with triptolide with/ without caspase inhibitors for 24 hours,
 after which fragmented DNA in the cytoplasm was measured by enzyme immunoassay and the
 fold induction of DNA fragmentation was calculated relative to the control value (untreated
 cells). Data are the mean Å} S.D. for triplicate cultures and representative results from 3
 independent experiments are shown. ", p Åq O.05 versus cells treated with triptolide alone.
 Significance was evaluated by Student's t-test with a Bonferroni's correction in each caspase
 inhibitor study.
2'7 Effect oftriptolide on PPARy activation
    To explore whether PPARy activation was involved in the apoptotic effect of
triptolide, I performed a luciferase reporter gene assay by co'transfection of RA synovial
fibroblasts with a PPRE'driven luciferase reporter plasmid and a PPARy expression
plasmid (Figure 27). Incubation with 15dPGJ2, a PPARy ligand, significantly induced
PPRE'driven luciferase activity in this system. In contrast, triptolide had little
influence on PPARy activation despite causing the apoptosis of RA synovial fibroblasts.
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Figure 27. Effect of triptolide on activation of PPARy in RA synovlal fibroblasts. Cells were
co-transfected with a PPRE-driven luciferase reporter plasmid, a PPARy expression plasmid, and
an internal control plasmid. Then the transfected cells were treated with known PPARy ligand or
triptolide and luciferase activity was determined as described in Materials and Methods. Data are
the mean Å} S.D. for triplicate cultures and representative results from 3 independent experiments
are shown. *, p Åq O.05 versus other groups. Significance was evaluated by Student's t-test with a
Bonferroni's correction.
2-8 Effect ofan extract of'Itipterygium wilfordli Hook F. on DNA fragmentation
   Since triptolide was regarded as a major active compound of GTW, an extract of
'I'WHF, I examined whether GTW induced apoptosis in RA synovial fibroblasts. As show
in Figure 28, GTW induced DNA fragmentation in RA synovial fibroblasts at 10 to 30
pg/mL. With GTW at 50 pg/mL, the cells had undergone secondary (type 2) necrosis,
which usually occurs after apoptosis during in vr'tro experiments.
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Figure 28. Effect of GTW
incubated with GTW for 24 hours
by empe immunoassay and the fold induction ofDNA fragmentation was calculated relative to
the control value (untreated cells). Data are the mean Å} S.D. for triplicate cultures and
representative results from 3 independent experiments are shown. *, p Åq O.Ol versus untreated
control cells. Significance was evaluated by Student's t-test with a Bonferroni's correction.
     Concentration (IAg/mL)
DNA ftagmentation in RA synovial fibroblasts. Cells were
, after which fragmented DNA in the cytoplasm was measured
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3. Discussion
       This study showed that triptolide, which has been identi{}ed as a major active
compound in TWHF extract, induced the apoptosis of RA synovial fibroblasts. Triptolide
as well as TWHF extracts have been shown to inhibit cell growth by induction of
apoptosis in several kinds of lymphocytes and cancer cell lines, as reviewed by Chen et
al.69). However, this is the fust evidence that triptolide induces apoptosis of RA synovial
fibroblasts.
       Extracts ofTWHF (T2 and GTW) and triptolide have very similar actions, such
as suppressing the production of NF'KB by T lymphocyteses), IL'8 by human bronchial
epithelial cells64), and PGE2 by human monocytes and RA synovial fibroblastseo,67).
Triptolide has been reported to display both immunosuppressive and anti'inflammatory
effectsM,67,70,7i). These findings suggest that it is a major active compound of TWHF
extracts.
       I already showed in chapter 1 and chapter 2 that RA is characterized by
extensive inflammation and proliferation ofthe synovium in various joints and synovial
hyperplasia leads to joint destruction. Therefore, the identification of agents that induce
apoptosis of RA synovial fibroblasts may be a key step toward the successful treatment
of RA. Our finding that triptolide induces the apoptosis of RA synovial fibroblasts may
help to explain the anti'rheumatic effect of TWHF extract in clinical studies50).
Although I found that triptolide could induce the apoptosis of RA synovial fibroblasts,
standard DMARDs like methotrexate and sulphasalazine did not induce apoptosis.
Low'dose methotrexate and sulphasalazine have been reported to inhibit radiographic
progression ofjoint changes in patients with RA72•73). I found that triptolide and G'I'W
could induce the apoptosis of RA synovial fibroblasts, suggesting that triptolide might
-
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have a stronger effect than conventional DrmDs. Tao et al.5e studied the efficacy and
safety of TWHF extract in patients with RA. They found that 'IJWHF extract improved
the symptoms of RA according to American College of Rheumatology criteria. In
addition, it decreased C'reactive protein (CRP), rheumatoid factor, and the erythrocyte
sedimentation rate (ESR), changes that were not seen during treatment with NSAIDs.
       In the present study, activation of caspase'3 was increased when cells were
treated with triptolide (Figure 25). 'Iliis triptolide-induced activation of caspase'3 was
suppressed by Z'VAD'FMK, a pan'caspase inhibitor. Therefore, induction of apoptosis
by triptolide was dependent on the caspase'3 pathway. Our results showed those
inhibitors of not only caspase'3, but also caspases'8 and '9 suppressed triptolide
induced'DNA fragmentation in RA synovial fibroblasts (Figure 26). From these results,
it suggested that the activation ofcaspase'3 followed activities ofcaspase"8 or '9 would
take a part on triptolide inducing apoptosis. There are a lot of uncertati points of the
details though this suggestion is similar to the one stM shown in the chapter 2. Yang et
al.os) reported that over expression of Bcl'2, whieh inhibit mitochondrial intrinsic
pathway, suppressed triptolide induced degradation of poly ADP'ribose polymerase, a
caspase substrate, and apoptosis of T lymphocytes. In contrast, our data suggest that
triptolide'induced ap(rptosis in RA synovial fibroblasts was performed by both intrinsic
and extrinsic pathways.
       On the other hand, it was reported that 15dPGJ2 and troglitazone, natural and
synthetic ligand ofPPARy, respectively, could induce RA synoviocyte apoptosis in vitro7).
We previously found that some NSAIDs induce the apoptosis of RA synovial fibroblasts
in a COX'2'independent, but PPARy'dependent, manner9). We also reported that
celecoxib, a selective COX'2 inhibitor, induces apoptosis and suppresses the
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proliferation of RA synovial fibroblasts without activation of PPAR7 (chapter 1). In this
chapter, however, triptolide did not induce PPARy activation. Intracellular mechanism
of proapoptotic action of triptolide except for PPARy activation in RA synovial
fibroblasts is to be studied.
       There have been several reports suggesting the mechanism of
triptolide-induced apoptosis in cancer cell lines. Jiang et al.74) found that suppression of
p53 expression by an antisense oligonucleotide could prevent triptolide induced
apoptosis, while over'expression of dominant negative p53 abolished the inhibitory
effect on NF'KB activation in human gastric cancer cells. In contrast, it was reported
that triptolide has a broad spectrum of proapoptotic activity against several kinds of
cancer cells that express wild'tmpe or mutant forms ofp5375). Lee et al.76) suggested that
NF'icB is an important factor for proapoptotic action of triptolide on cancer cell lines.
Recently, Frese et al.77) reported that TNF-related apoptosis inducing ligand
(TRAIL)'induced apoptosis in lung cancer cells was sensitized by triptolide via
activation of extracellular signal'regulated kinase (ERK)2, a member of the
mitogen'activated protein kinase family. It might have to be examined whether such the
already'known mechanism of uiptolide inducing apoptosis takes part on RA synovial
fibroblast.
       In this study, GTW induced apoptosis in RA synovial fibroblasts in
concentration dependent manner. It was reported that triptolide and tripdiolide were
purified from aqueous extract ofTWHF70). Although I did not examine experiments with
tripdiolide, one ofthe major active compounds of GTW might be triptolide. Furthermore,
studies should be conducted to clarify the mechanism of the proapoptotic action of
triptolide in RA synovial fibroblasts.
-
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4. Conclusion
       I demonstrated that triptolide, an active compound, i
Chinese herb, induced apoptosis of RA synovial fibroblasts.
dentfie d in a ttaditional
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Summary
  Among the various mechanisms underlying the therapeutic effect of drugs treating
RA, induction of apoptosis in synovial cells was investigated in the present study and
the following findings were obtained.
   In chapter 1, six selective COX'2 inhibitors were investigated with respect to the
induction of apoptosis. As a result, it was confirmed that only celecoxib induced the
apoptosis of RA synovial cells. The other selective COX'2 inhibitors that were tested
did not induce apoptosis, and induction of apoptosis in RA synovial cells was not
observed even aftk)r incubation for a long period with rofecoxib at a concentration high
enough to inhibit COX'2. Therefore, it was shown that the apoptotic effect ofcelecoxib
on RA synovial cells was not related to inhibition of COX'2 and was unique to this drug.
However, celecoxib only induced apoptosis of RA synovial ceils at a higher concentration
than the blood level achieved after administration to healthy volunteer at the usual
clmical dose44), so it was considered necessary to take additional measures in order to
obtain an antirheumatic effect via the induction of apoptosis.
   Therefore, to find drugs with a stronger apoptotic effect than celecoxib, [['TIOI and
TT201 (celecoxib derivatives) were investigated with respect to induction ofapoptosis in
RA synovial cells during chapter 2. As a result, T"rlOl was found to have a stronger
apoptotic effect on RA synovial cells than celecoxib, while the effect of T201 was
weaker than that of celecoxib. It was also shown that the inhibitory effect of TTIOI on
PGE2 production was weaker than that of celecoxib and that the apoptotic effect of
TTIOI was unrelated to inhibition of COX"2. To clarify the cellular selectivity of the
apoptotic effect of TTIOI, its activity was also investigated using OA synovial cells and
U937 cells. As a result, TTIO1 was shown to markedly induce apoptosis in OA synovial
-
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cells and U937 cells as well as RA synovial ceils, so induction of apoptosis by TIOI
showed no cellular selectivity among the cell types investigated in the present study.
  In chapter 3, triptolide (an active ingredient of TWHF, which is a herbal medicine
used clinically in China to treat autoimmune diseases such as RA and control
post'transplantation rejectionl was investigated to assess its induction of apoptosis in
RA synovial cells. As a result, it was shown that triptolide induced apoptosis in RA
synovial cells. As reported previously, the main pharmacological effect of TwnF was
on cells with a role in the process ofinflammation, including T cells. Since the present
study showed that triptolide (an active ingredient of TWHF) induees apoptosis of RA
synovial cells, it can be suggested that TWHF has a new mechanism of action, which is
inhibition of the abnormal proliferation of synovial tissue that plays an important role
in the pathogenesis of RA.
       These results indicate that some of NSAIDs and ingredients of Chinese herbal
medicines may exhibit an antihyperplastic effect by promoting the apoptosis of RA
synovial cells. Clinical application of such an antihyperplastic effect on synovial cells
for the treatment ofRAwill require further research. However, unlike the well'known
anti'inflammatory effect of these agents, the apoptotic effect revealed by the present
study could contro1 the mechanism involved in the pathogenesis of articular disease in
RA, which expands the possibility for clinical application ofthese drugs. Furthermore,
detailed investigation ofthe structures ofcelecoxib, 'I"TIO1, and triptolide may lead to a
new class of RA therapeutics that act by inducing the apoptosis of RA synovial ceils.
-
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Materials and Methods
1. Chapter1
1-1
    Materials
Celecoxib
    4-[5'(4'MethylphenyD'3'(trifluoromethyD'IH'pyrazol'1'yl]benzenesulfonamide
    (synthesized using previously reported methods and obtained ftom Pharmacia
    K K, Tokyo, Japan), molecular weight; 381.38.
    The purity of these celecoxib preparations was analyzed by highperformance
    liquid chromatography (HPLC) (1100 series; Agilent, Palo Alto, CA) using a
    Supelcosil LC'DP column (250 Å~ 4.6 mm internal diameter; Sigma, St. Louis,
    MO) packed with 5 pmdiameter particles as the stationary phase and a mobile
    phase of20 mM potassium phosphate (pH 3.0) / methanol (MeOH) / acetonitrile
    (MeCN) (6/3/1) at a fiow rate of 1.15 mL/minute and a temperature of 60 OC
    with ultraviolet (UV) detection at 215 nm. The retention times of the
    synthesized and the Pharmacia'obtained celecoxib preparations were identical
    (25 minutes), and their purities were 99.95 O/o and 99.94 O/o, respectively.
Etodolac
    1,8'Diethyl'1,3,4,9'tetrahydropyrano[3,4'b]indole"1'acetic acid (Wyeth Lederle
    Japan, Tbkyo, Japan), molecular weight; 287.35.
Meloxicam
    4'Hydroxy'2'methyl'2V (5'methyl"2'thiazolyD'2ff 1,2'benzothiazine'3bcarboxa
    mide'1,1'dioxide (Nippon Boehringer Ingelheim, Osaka, Japan), molecular
    weight; 351.41.
Nimesulide
-
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       AF(4'Nitro-2-phenoxy'phenyDmethanesulfonamide, (Cayman Chemical, Ann
       Atbor, MI), molecular weight; 308.31.
   NS-398
       AF[2'(CyclohexyloxyD'4'nitrophenyl]"methanesulfonamide,
       (Cayman ChemicaD, molecular weight; 314.4.
   Rofecoxib
       4'[4'(MethylsulfonyD'phenyl]'3-phenyl'2(5H)'furanone (synthesized using
       previously reported methods78)), molecular weight; 314.36.
   Indometacin
       1'(4'ChlorobenzoyD'5'methoxy-2"methylindol'3'acetic acid (Sigina Chemical
       Co., St. Louis, MO), molecular weight; 357.8.
   Tltroglitazone
       5'[{4'[(3,4-Dihydro'6"hydroxy'2,5,7,8-tetramethyl'2H'1'benzopyran'2'yDmetho
       xy]"phenyllmethyll'2,4-thiazolidinedione (Sankyo Co., Ltd., Tokyo, Japan),
       molecular weight; 441.55.
   NSAIDs and troglitazone were dissolved in dimethyl sulfoxide (DMSO) to make
stock solutions. The final concentration of DMSO was O.1 O/e (v/v) in the cell culture
medium.
   RPMI 1640 medium, penicillinlstreptomycin solution, fetal bovine serum (FBS), and
O.25 O/o trypsinEDTA were purchased from Gibco BRL (Gaithersburg, MD).
Phosphate'buffered saline (PBS) (') were purchased from Takara Shuzo Co., Ltd, (Shiga,
Japan). Z'DEVD'FMK (a caspase-3 inhibitor) and Z'IETD'FMK (a caspase'8 inhibitor)
were purchased from R&D Systems (Minneapolis, MN). Z-VAD-FMK (a caspase'317
inhibitor) was purchased from Promega (Madison, WI). IL-IP was purchased from
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Genzyme (Cambridge, MA). An other chemicals were purchased from Wako (Osaka,
Japan).
1-2 Cell culture
   RA synovial tissue specimens were obtained during total knee replacement surgery
in patients with RA that fulfilled the revised criteria of the Arnerican College of
Rheumatology (formerly, the American Rheumatigm Association)i,79•eo). The protocol for
this study was approved by the St. Marianna University Ethics Committee, and all
patients gave written consent to the use of their tissue for this research. RA synovial
fibroblasts were prepared from synovial tissue as described previously27'. Synovial
tissue was digested for 2 hours with O.2 O/o (w/v) bacterial collagenase (Immuno'
Biological Laboratories, Gunma, Japan) and then was suspended in RPMI 1640 with
10 O/o (v/v) FBS, 100 units/mL penicil1in, and 1oo pglmL streptomycin. The cells were
incubated at 37 OC in 5 O/o C02 for several days, after which nonadherent cells were
removed. Fibroblast'like adherent cells from the first or second passage were used as
RA synovial fibroblasts.
1'3 Assay ofprostaglandin E2 production
   RA synovial fibroblasts were plated in 24'well plagtic plates (1 Å~ le5 cells/welD and
cultured for 24 hours. After washing with PBS (9.57 mM, pH 7.35'7.65), the cells were
incubated for 1 hour at 370C with various concentrations of celecoxib, etodolac,
meloxicam, nimesulide, NS'398, or rofecoxib in RPMI 1640 containing 1 O/o(vlv) FBS,
100 units/mL penicillin, and 100 pglmL streptomycin in an atmosphere of 5 O/o C02.
Then, 3 lilvr arachidonic acid (Cayman ChemicaD was added to each well. After
incubation for 30 minutes, the culture medium was harvested using a syringe and
filtered with a O.22-pm filter ampore, Bedford, mo. The PGE2 concentration in the
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medium was measured using an EHSA kit according to the instructions of the
manufacturer (Cayman ChemicaD. Each measurement was done in triplicate.
1'4 Cell proliferation
   The proliferation of RA synovial fibroblast was estimated from the incorporation of
BrdU. Cells (1 Å~ 104 cellslwell) were incubated in 96'well plastic plates with the test
drugs in RPMI 1640 containing 1 O/o (vlv) FBS for 24 hours at 37 OC in an atmosphere of
5 O/o C02. After incubation, BrdU (10 IiM) was added to the culture medium, and then
the cells were incubated for another 18 hours. Subsequently, the cells were fixed and
BrdU incorporation was determined with a Cell Proliferation ELISA Kit aceording to
the instructions of the manufacturer (Reche Diagnostics, Mannheim, Germany). Each
measurement was done in triplicate, and the results are presented as percentages
relative to the value determined with untreated contro1 cultures.
1'5 Cell viabmaty
   RA synovial fibroblasts tz Å~ 104 cellsiwell) were incubated at 37 OC in 96'well plastic
plates with test drugs in RPMI 1640 containing 1 O/o (v/v) FBS in an atmosphere of5 O/o
C02. After 24'96 hours, cell viability was assessed by measuring mitochondrial
NADH'dependent dehydrogenase activity with a Cell Counting Kit (Dojindo Molecular
Technologies, Kumamoto, Japan) using WST'1. Each measurement was done in
triplicate, and the results are presented as percentages relative to the value determined
with untreated control cultures.
1'6 DNA fragmentation
   RA synovial fibroblasts were plated in 96'well plastic plates (2 Å~ 104 cells/welD and
cultured for 24 hours. The cells were then incubated for a further 24 hours at 37 OC with
test drugs in RPMI 1640 containing 1 O/e FBS (v/v). After incubation, DNA
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fragmentation was measured using a Cell Death Detection ELISAPLUS kit (Roche
Diagnostics). Each measurement was done in triplicate, and the results are presented
as the fold induction compared with untreated control cultures.
1'7 TUNEL assay
   RA synovial fibroblasts (2.5 Å~ 104 cells/well) were incubated in 8'well chamber slides
(Iwaki, Chiba, Japanl for 24 hours at 37 OC with the test drugs in RPM[ 1640 containing
1 O/o (v/v) FBS. Morphologic changes of the cells were observed under a microscope
(BX51; Olympus, Nagano, Japan), after which the cells were fixed with 4 O/e (v/v) neutral
buffered formalm for 10 minutes at room temperature. Subsequently, apoptotic synovial
fibroblasts were identified with the TUNEL assay, using an Apoptosis in situ Detection
Kit according to the instructions of the manufacturer (Wako). Sections were
counterstained with methyl green (Wako) before observation.
1'8 Effects ofcaspase inhibitors on celecoxib'induced apoptosis
   RA synovial fibroblasts were plated in 96"well plastic plates (2 Å~ 104 cellsiweM and
cultured for 24 hours. The cells were then incubated for a further 24 hours at 37 OC with
celecoxib with/without Z'DEVD'FMK (a caspase'3 inhibitor), Z'IETD'FMK (a caspase'8
inhibitor), or Z'VAD'FMK (a caspase'3/7inhibitor) in RPMI 1640 containing 1 O/o (v/v)
FBS. After incubation, DNA fragmentation was measured using a Cell Death Detection
EHSAPLUS kit (Roche Diagnostics). Each measurement was done in triplicate, and the
results are presented as the fold induction compared with untreated contro1 cultures.
1'9 Effect of lnterleukn'IP on celecoxib'induced apoptosis
   RA synovial fibroblasts were plated in 96'well plastic plates (2 Å~ 104 cellsXwelD and
cultured for 24 hours. The cells were then incubated for a further 24 hours at 37 OC
with/without IL'IP (1 nglML) in RPMI 1640 contaming 1 O/o (v/v) FBS. After incubation,
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celecoxib or rofecoxib were added to the culture medium, and then the eells were
incubated for another 24 hours. Subsequently, the cells DNA fragmentation was
measured using a Cell Death Detection ELISAPLUS kit (Roche Diagnostics). Each
measurement was done in triplicate, and the results are presented as the fold induction
compared with untreated contro1 cultures.
1'10 Assay of transcriptional activation of PPARy
   A Iuciferase reporter plasmid, containing 4 copies ofthe PPRE ofthe acyl'coenzyme
A oxidase gene promoter at the Nhe I restriction site in the firefly luciferase expression
vector PGV-P2 ('Ibye, 'Ibkyo, Japan), was used to measure PPARy activation8i). RA
synovial fibroblasts (6 Å~ 104 cellsiwelD were seeded into 24'well culture plates in RPmu
1640 containing 10 e/o (v/v) FBS. After culture for 24 hours at 37 OC in an atmosphere of
5 O/o C02, the ceils were co'transfected with the reporter plasmid (O.1 pgl well), a PPARy
expression plasmid containing mouse PPAR72 complementary DNA at the HindIII and
.815a I restriction sites in the expression vector pRc/CMV (O.1 pg/well; Invitrogen,
Groningen, The Netherlands), and an internal control plasmid (pRL'SV40) (O.Ol
pgtwell; Promega), using Effectene 'Iltransfection Reagent (12 pg/mL) according to the
instructions of the manufacturer (Qiagen, Hilden, Germany). Incubation was continued
for a further 24 hours at 37 OC in an atmosphere of5 O/o C02, and then the transfection
mixture was replaced by RPMI 1640 containing 1 O/o (v/v) FBS with or without one of the
test drugs. After an additional ineubation for 18 hours at 37 OC in an atmosphere of 5 O/o
C02, luciferase activity was determined using the Dua!'Luciferase Reporter Assay
System (Promega) and a TD'20120 luminometer, according to the instructions of the
manufacturer ('IUrner Designs, Sunnyvale, CA). Each measurement was done in
triplicate, and firefly luciferase activity was normalined to Renilla luciferase activity.
-
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Chapter 2
    Materials
TT1O1
    IV (2 'Aminoethyl)'4' [5'(4'tolyD'3'(trifluoromethyD' IH"pyrazol' 1'yl]benzenesulf
    onamide (kindly provided by Professor H. Handa (Tokyo Institute of Technology,
    Yokohama, Japan)), molecular weight; 370.48
    The purity of TTIOI was År 99 O/o, as assessed by HPLC under the following
    conditions: MeOH solution (1 mg/mL) was injected into the L'column
    octadecylsilane (4.6 Å~ 150 mm), and the mobile phase was MeCN / 20 mM
    phosphate buffer (pH 6.5) (35:65) at a fiow rate of 1 mWmin. 'ITIOI was
    detected with a UV detector at a wavelength of 254 nm and a retention time of
    21.2 min. iH NMR (DMSO'd6), 6 2.31 (s, 3H), 2.50 (br, 5H), 2.76 (t, J -- 7.0 Hz,
    2H), 7.20 (br, 5H), 7.55 (dd, J = 2.0, 6.0 Hz, 2H), and 7.84 (dd, J = 2.0, 6.0 Hz,
    2H).
TT201
    4'{5'(4'AminophenyD-3'(trifluoromethyD'IH'pyrazol'1'yljbenzenesulfonamide
    (kindly provided by Professor H. Handa (Tokyo Institute of Technology,
    Yokohama, Japan)), molecular weight; 370.48, m.p., 202-203 OC.
    The purity of TT201 was År 99 O/o, as assessed by HPLC under the following
    conditions: MeOH solution (1 mg/mL) was injected into the L'column
    octadecylsilane (4.6 Å~ 150 mm), and the mobile phase was MeCN 1 20 mM
    phosphate buffer (pH 6.5) (1:1) at a flow rate of 1 mWmin. [['T201, as previously
    reported by Penning et al.82), was detected with a UV detector at a wavelength
    of254 nm and a retention time of8.6 min. Rofecoxib was synthesized as
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       reported elsewhere78).
   Celecoxib
       4'[5'(4'MethylphenyD'3'(trifluoromethyD'IH-pyrazoH'yl]benzenesulfonamide
       (Pfizer Japan Inc., Tokyo, Japan), molecular weight; 381.38.
   SC-236
       4'[5'(4'ChlorophenyD'3'(trifluoromethyD'IH'pyrazol'1'yl]benzenesulfonamide
       (Pfizer Japan Inc., Tokyo, Japan), molecular weight; 347.83.
   Rofecoxib
       4'[4'(MethylsulfonyD'phenyll'3'phenyl'2(5fi)'furanone (synthesized using
       previously reported methodseo)), molecular weight; 314.36.
   NSAIDs were dissolved in DMSO to make stock solutions. 'I'he final concentration of
DMSO was O.1 e/o (vlv) in the cell culture medium. Z-DEVD-FMK, Z-IETD'FMK, IL-IP,
FBS, RPMI 1640 medium, penicillin/streptomycin solution, O.25 O/e trypsin/EDTA, and
PBS were same in chapter 1. Z'IEHD'FMK (a caspase'9 inhibitor) was purchased from
R&D Systems.
2'2 Cell culture of synovial fibroblast
   Synovial fibroblast cells were prepared by the method of chapter 1.
2'3 Cell culture of U937
   U937 cells were kindly provided by Professor H. Kitasato (Kitasato University
School of Medical Science, Kanagawa, Japan). Cells were washed with RPMI 1640
containing 10 O/o(v/v) FBS, 100 units/mL penicillin, and 100 pg/mL. Then, the cells were
incubated at 37 OC in 5 O/o C02 for several days.
2'4 Cell proliferation
   The proliferation of RA or OA synovial fibroblast was estimated from the
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incorporation ofBrdU. Cells (1 Å~ 104 cellslwel}) were incubated in 96-well plastic plates
with the test drugs in RPMI 1640 containing1 O/o (vlv) FBS for 24 hours at 37 OC in an
atmosphere of 5 e/o C02. After incubation, BrdU (10 ltlva) was added to the culture
medium, and then the cells were incubated for another 18 hours. Subsequently, the cells
were fixed and BrdU incorporation was determined with a Cell Proliferation ELISA Kit
according to the instructions of the manufacturer (Roche Diagnostics). Each
measurement was done in uiplicate, and the results are presented as percentages
relative to the value determined with untreated control cultures.
2'5 Cell viabMty
   RA or OA synovial fibroblasts (2 x 104 cells/welD were incubated at 37 OC in 96'well
plastic plates with test drugs in RPMI 1640 containing 1 O/o (v/v) FBS in an atmosphere
of 5 O/o C02. After 24 hours, cell viability was assessed by measuring mitochondrial
NADH'dependent dehydrogenase activity with a Ceil Counting Kit (Dojm' do Molecular
Technologies) using WSTL1. Each measurement was done in triplicate, and the results
are presented as percentages relative to the value determined with untreated control
cultures.
2'6 DNA fragrnentation
   RA or OA synovial fibroblasts were plated in 96'well plastic plates (2 Å~ 104 cellsiwelD
and cultured for 24 hours. The cells were then incubated for a further 24 hours at 37 OC
with test drugs in RPM[ 1640 containing 1 O/o (v/v) FBS. After incubation, DNA
fragmentation was measured using a Cell Death Detection EllISAPLUS kit (Roehe
Diagnostics). Each measurement was done in triplicate, and the results are presented
as the fold induction compared with untreated control cultures.
2'7 Activity of caspase'3
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   RA synovial fibroblasts were incubated in tissue culture flasks in the presence or
absence of TTIOI and/or Z'IETD'FMK and Z'IEHD'FMK under the conditions
described above. After 24 hours, cellular caspase'3 activity was measured by using the
CaspACE assay system (Promega Corporation) in accordance with the manufacturer's
instructions. Then the cens were washed in ice'cold PBS and resuspended in cell lysis
buffer. After lysis ofthe oells by freezing and thawing, the lysates were centrifUged, and
the supernatants were used as cell extracts. The protein content of each extract was
determined by the bicinchoninic acid (BCA) protein assay method (Pierce Biotechnology,
Rockford, IL) with bovine serum albumin (BSA) as the standard, and the protein
content ofwas adjusted to 1 mg/mL.
2'8 Effects of caspase inhibitors on 'I"TIOI'induced apoptosis
   RA synovial fibroblasts were plated in 96'well plastic plates (2 x 104 cellsiwell) and
cultured for 24 hours. The cells were then incubated for a further 24 hours at 37 OC with
celecoxib with/without Z'DEVD'FMK (a caspase'3 inhibitor), Z'IETD'FMK (a caspase'8
inhibitor), or Z'LEHD'FMK (caspase'9 inhibitor) in RPINdi 1640 contaming 1 O/o (v/v)
FBS. After incubation, DNA fragmentation was measured using a Cell Death Detection
ELISAPLUS kit (Roche Diagnostics). Each measurement was done in duplicate, and the
results are presented as the fold induction compared with untreated contro1 cultures.
2'9 Western blotting analysis
   RA synovial fibroblasts were lysed in Chaps cell extract buffer (50 mM PipeslHCI,
pH 6.5, O.1 O/o (wlv) Chaps, 5 mM dithiothreito1, 2 mM EDTA, 10 pg/mL pepstatin, 20
pg/mL leupeptin, and 10 pg/tnL aprotinin) and then centrifuged at 14,Ooo rpm for 30
min to remove debris. Subsequently, the protein content of the supernatant was
determined by the BCA protein assay (Pierce Biotechnology) with bovine serum
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albumin as the standard, and the protein content of the extracts was adjusted to 1
mg/mL. Then the extracts were subjected to sodium dodecyl sulfate'polyacrylamide gel
electrophoresis using 15 O/o (wlv) acrylamide slab gels under reducing conditions. The
proteins thus separated were electroblotted onto Immobilon'P poly (vinylidene
difluoride) membranes (Millipore Corporationl with a semidry blotter (Atto Technology,
Inc., Tokyo, Japan). After the membranes had been blocked in 10 mh TBS contaming
O.1 O/o(v/v) 'I]ween 20 (TBS'T) and 5 O/o(w/v) skim milk for 1 hour at room temperature,
rabbit anti'Bcl'2 polyclonal antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA)
or rabbit anti-BID polyclonal antibody (Cell Signaling Technology, Inc., Beverly, mo
was applied for 18 hours at 4 OC. Then the membranes were washed with Tris buffered
saline'tween (TBS'T), and incubation with the secondary antibody (horseradish
peroxidase conjugated goat anti'rabbit antibody at a dilution of 1:10,OOO in TBS'T) was
performed for 1 hour. After further washing with TBS'T, the protein bands were
detected by using an enhanced chemiluminescence Western blot analysis system.
2'10 Effect of rofecoxib on TTIOI'induced apoptosis
   RA synovial fibroblasts were plated in 96'well plastic plates (2 Å~ 104 cellsiwell) and
cultured for 24 hours. The cells were then incubated with/without rofecoxib for 1 hour,
and 'T"rlOl was added to the medium for a further 24 hours at 37 OC. After incubation,
DNA fragmentation was measured using a Cell Death Detection ELISAPLUS kit (Roche
Diagnostics). Each measurement was done in triplicate, and the results are presented
as the fold induction compared with untreated control cultures.
2-11 Assay ofprostaglandin E2 production
     RA synovial fibroblasts were incubated in 24'well plates (5 Å~ 105 cells/weM with
IL'IP (1 ng/mL) for 18 hours washed with PBS and then exposed to the test drugs for 1
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hour under the conditions described above. Then 3 pM arachidonic acid (Cayman
ChemicaD was added to the medium. After incubation for 30 minutes, the culture
medium was harvested using a syringe and fi1tered through a O.22'pm ruter (Millipore
Corporation). The PGE2 concentration in the medium was measured using an ELISA kit
(Cayman ChemicaD in aceordance with the manufacturer's instructions. Each
measurement was performed in triplicate.
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'Itiptolide
    (BIOMOL Research
    weight; 360.4
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        Figure 29. Chemical structure oftriptolide
Bucillamine
    AF(2'Mercapto-2'methyltl'oxopropyD'L'cysteine (Sigma Chemical Co.),
    molecular weight; 223.32
Methotrexate
    AF[4'[[(2,4'Diamino'6'pteridinyl)methyl]methylamino]benzoyl}'L'glutamic acid
    (Wako Pure Chemical Industries, Osaka, Japan), molecular weight; 454.44
D'Penicillamine
    3'Mercapto'D-valine (Sigma Chemical Co.), molecular weight; 149.21
Sodium aurothiomalate
    Mixture of monogold monosodium monohydrogen(RS)'1'suHidobutane'
    1,2'dioate and monogold disodium(RS)'1-sulfidobutane'1,2'dioate (Shienogi &
    Co. Ltd., Osaka, Japan), molecular weight; 390.08, 368.09, respectively
Sulphasalazine
    2'Hydroxy'5'[4'(pyridin'2'ylsulfamoyDphenylazolbenzoic acid (Sigma
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       Chemical Co.), molecular weight; 398.39
   15dPGJ2
       11'Oxo'prosta"5Z,9,12E,14Z'tetraen-1'oic acid (Cayman ChemicaD, molecular
       weight; 316.4.
   GTW was kindly given ftom Taizhou Pharmaeeutical Co. (Jiang Su, China).
   FBS, RPmu 1640 medium, penicillin/streptomycin solution, O.25 O/o trypsin/EDTA,
and PBS were the same as in chapter 1. Z'VAD'FMK was the same as in chapter 1.
Z'DEVD'FMK, Z'IETD'FMK, and Z'LEHD'F]Nfll were the same as in chapter 2. Test
drugs except GTW were dissolved in DMSO as 1000 Å~ stoek solutions and then diluted
with RPMI'1640 medium containing 1 O/o (v/v) FBS for cell culture experiments. GTW
powder was dissolved in ethanol, filtrated, and then stored at '20 OC. Test drug solutions
were prepared freshly on the day of use. The final concentration of DMSO or ethanol
liust for GTW study) for all treatments (including control cultures) was O.1 O/o (v/v).
3-2 Cell culture
   Synovial fibroblast cells were prepared by the method ofchapter 1.
3'3 Cell proliferation
   The proliferation of RA synovial fibroblast was examined by the method which was
same as in chapter 1.
3'4 Cell viabthty
   RA synovial fibroblasts (2 Å~ 104 cells/welD were incubated at 37 QC in 96'well plastic
plates with test drugs in RPMI 1640 containing 1 O/o (v/v) FBS in an atmosphere of5 O/o
C02. After 24 hours, cell viability was assessed by measuring mitochondrial
NADH'dependent dehydrogenase activity with a Cell Counting Kit (Dojindo Molecular
'I]echnologies) using WS[[Ll. Each measurement was done in triplicate, and the results
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are presented as percentages relative to the value determined with untreated control
cultures
3'5 DNA fragmentation
   The DNA fragmentation of RA synovial fibroblast was examined by the method
which was same as in chapter 1.
3-6 TUNEL assay
   TUNEL assay of RA synovial fibroblast was examined by the method which was
same as in chapter 1.
3'7 Activity of caspase-3
   RA synovial fibroblasts were incubated in tissue culture flasks in the presence or
absence of triptolide andlor Z'VAD'FMK under the con(litions described above. After 24
hours, cellular caspase'3 activity was measured by using the CaspACE assay system
(Promega Corporation) in accordance with the manufacturer's instructions. Then the
cells were washed in ice'cold PBS and resuspended in cell lysis buffer. After lysis of the
cells by fteezing and thawing, the lysates were centrifuged, and the supernatants were
used as cell extracts. The protein content of each extract was determined by the BCA
pretein agsay method (Pierce Biotechnology) with BSA as the standard, and the protein
content ofwas adjusted to 1 mglmL.
3'8 Effects of caspase inhibitors on triptolide'induced apoptosis
   RA synovial fibroblasts were plated in 96'well plastic plates (2 Å~ 104 cellsiwell) and
cultured for 24 hours. The cells were then incubated for a further 24 hours at 37 OC with
triptolide with/without Z'DEVD-FMK, Z'IETD'FMK, or Z'LEHD'FMK in RPIxu 1640
containing 1 O/o (vlv) FBS. After incubation, DNA fragmentation was measured using a
Cell Death Detection ELISAPLUS kit (Roche Diagnostics). Each measurement was done
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in duplicate, and the results are presented as the fold induction compared with
untreated contro1 cultures.
3'9 Assay of transcriptional activity of PPARy
   RA synovial fibroblasts (6 Å~ 104 cells/well) were seeded into 24'well culture plates in
RPMI 1640 containing 10 O/o (v/v) FBS. After culture for 24 hours at 37 OC in an
atmosphere of 5 O/o C02, the cells were co'transfected with the reporter plasmid, a
PPARy expression plasmid, and an internal contro1 plasmid by the same method as in
chapter 1. Incubation was continued for a further 24 hours at 37 OC in an atmosphere of
5 O/o C02, and then the transfection mixture was replaced by RPMI 1640 containing 1 O/o
(vlv) FBS with or without one of the test drugs. After an additional incubation for 18
hours at 370C in an atmosphere of 5 O/o C02, luciferase activity was determined using
the Dual'Luciferase Reporter Assay System (Promega) and a TD"20/20 luminometer,
according to the instructions ofthe manufacturer (Turner Designs). Each measurement
was done in niplicate, and firefly luciferase activity vvas normalized to Renilla
luciferase activity.
-
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